Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 18, 2016 09:08 ET | Source: Cynapsus Therapeutics Inc.

Cynapsus Therapeutics Obtains Final Court Order and HSR Waiting Period Expires for Plan of Arrangement with Sunovion Pharmaceuticals

TORONTO, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (“Cynapsus”) (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system pharmaceutical company developing a fast-acting,...
October 13, 2016 16:00 ET | Source: Cynapsus Therapeutics Inc.

Cynapsus Therapeutics Securityholders Approve the Plan of Arrangement with Sunovion Pharmaceuticals

TORONTO, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (“Cynapsus”) (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system pharmaceutical company developing a fast-acting,...
September 28, 2016 19:27 ET | Source: Cynapsus Therapeutics Inc.

ISS Recommends Cynapsus Therapeutics Securityholders Vote for the Plan of Arrangement

TORONTO, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (“Cynapsus”) (NASDAQ:CYNA) (TSX:CTH) is pleased to announce today that Institutional Shareholder Services (“ISS”), a leading...
August 29, 2016 06:00 ET | Source: Cynapsus Therapeutics Inc.

Cynapsus Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease

TORONTO, Aug. 29, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for...
August 15, 2016 06:00 ET | Source: Cynapsus Therapeutics Inc.

Cynapsus Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson’s Disease Clinical Study Allowing for At-Home Titration

TORONTO, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system (CNS) pharmaceutical company developing and preparing to...
August 12, 2016 06:00 ET | Source: Cynapsus Therapeutics Inc.

Cynapsus Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease

- Results suggests APL-130277 rapidly and effectively converts patients from the OFF to full ON state - - Manuscript published online ahead of print -TORONTO, Aug. 12, 2016 (GLOBE NEWSWIRE) --...
August 10, 2016 16:10 ET | Source: Cynapsus Therapeutics Inc.

Cynapsus Therapeutics Reports Second Quarter 2016 Financial Results and Recent Developments

- Recent Positive Dose Titration Data from Pivotal Phase 3 Clinical Program -- On Track for New Drug Application Submission in the First Half of 2017 - TORONTO, Aug. 10, 2016 (GLOBE NEWSWIRE) --...
July 18, 2016 16:10 ET | Source: Cynapsus Therapeutics Inc.

Cynapsus Therapeutics Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease

-- Company plans to initiate pivotal program in fourth quarter ---- Webcast with accompanying slides to discuss program tomorrow at 7:30 a.m. Eastern time --TORONTO, July 18, 2016 (GLOBE NEWSWIRE)...
July 18, 2016 16:10 ET | Source: Cynapsus Therapeutics Inc.

Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease

-- Webcast with accompanying slides to discuss these findings tomorrow at 7:30 a.m. Eastern time Top-line CTH-300 results expected in late Q3 or early Q4 -- TORONTO, July 18, 2016 (GLOBE NEWSWIRE)...
July 06, 2016 06:00 ET | Source: Cynapsus Therapeutics Inc.

Cynapsus Therapeutics Announces 2016 Analyst and Investor Day

TORONTO, July 06, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system (CNS) pharmaceutical company developing and preparing to...